文献速递类风湿关节炎

早期类风湿关节炎中糖皮质激素治疗与PCSK9水平升高独立相关:一项随机对照试验数据

Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: data from a randomised controlled trial.
PubMed 文献 · RMD Open · 2025-06-05

本研究为NORD-STAR试验的事后分析,纳入296例新诊断类风湿关节炎患者,均起始甲氨蝶呤并分别联合糖皮质激素、 certolizumab pegol、阿巴西普或托珠单抗。24周时糖皮质激素组PCSK9水平高于bDMARD联合组,在自身抗体阳性患者中升高更明显;LDL胆固醇在所有治疗组均升高。

要点

  • 24周时糖皮质激素组PCSK9水平高于bDMARD联合治疗组,差值-276.0(95%CI -468.2至-83.9)。
  • 与bDMARD治疗相比,糖皮质激素相关PCSK9升高在自身抗体阳性患者中更明显。
  • LDL胆固醇变化模式与PCSK9不同,在所有治疗组中均升高。

核心结论

  • 糖皮质激素治疗与24周后PCSK9水平升高相关。
  • 与bDMARD治疗相比,糖皮质激素相关PCSK9升高在类风湿因子、抗瓜氨酸化蛋白抗体和抗核抗体阳性患者中更明显。
  • 作者认为数据提供了糖皮质激素治疗与心血管疾病之间的潜在机制联系。

研究设计与样本

  • NORD-STAR试验的事后分析,纳入296例新诊断并起始甲氨蝶呤的类风湿关节炎患者。
  • 患者分别接受糖皮质激素、certolizumab pegol、阿巴西普或托珠单抗治疗。
  • 在基线和24周测量血清PCSK9和LDL胆固醇水平,采用线性回归模型分析24周时糖皮质激素与bDMARD治疗间PCSK9和LDL胆固醇差异。
  • 第二项分析在模型中纳入治疗组与自身抗体状态的交互作用。

主要发现

  • 24周后糖皮质激素组PCSK9水平高于bDMARD联合治疗组,差值为-276.0(95%CI -468.2至-83.9)。
  • 与bDMARD治疗相比,糖皮质激素相关PCSK9升高在自身抗体阳性患者中更明显。
  • LDL胆固醇变化模式与PCSK9不同,在所有治疗组中均升高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rheumatoid arthritis elevates cardiovascular disease risk. Proprotein convertase subtilisin/kexin type 9 (PCSK9), a regulator of low-density lipoprotein (LDL) metabolism, increases LDL-receptor breakdown in the liver, which elevates LDL-cholesterol levels. In addition, PCSK9 has direct effects on thrombogenesis and atherosclerotic plaque formation.We aimed to investigate (1) the impact of glucocorticoids and biological disease-modifying antirheumatic drug (bDMARD) treatments on PCSK9 and LDL-cholesterol levels, (2) whether this influence is different when autoantibodies are present and (3) the association between PCSK9 and LDL cholesterol. METHODS: In this post hoc analysis of the NORD-STAR trial, 296 newly diagnosed patients starting methotrexate with glucocorticoids, certolizumab pegol, abatacept or tocilizumab were included. Serum PCSK9 and LDL-cholesterol levels were measured at baseline and 24 weeks. Linear regression models were used to analyse the difference in PCSK9 and LDL cholesterol between glucocorticoid and bDMARD treatments at 24 weeks. In the second analysis, the interactions between the treatment groups and autoantibody status were added to the model. RESULTS: After 24 weeks, PCSK9 levels were higher in the glucocorticoid group than in the combined bDMARD treatment group (-276.0 (95% CI -468.2 to -83.9)). When compared with the bDMARD treatment, these increases were more pronounced in autoantibody-positive patients. Changes in LDL cholesterol exhibited a pattern distinct from PCSK9, as it increased in all treatments. CONCLUSION: Glucocorticoid treatment was associated with increased PCSK9 levels after 24 weeks. When compared with the bDMARD treatments, these increases were more pronounced in rheumatoid factor, anticitrullinated protein antibody and antinuclear antibody-positive patients. Our data provide a potential mechanistic link between glucocorticoid treatment and cardiovascular disease. FUNDING: Inger Bendix Foundation for Medical Research. TRIAL REGISTRATION NUMBER: EudraCT2011-004720-35, NCT01491815.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Lend K, Twisk JW, Kumar N, et al. Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: data from a randomised controlled trial. RMD Open. 2025. PMID: 40480650. doi:10.1136/rmdopen-2024-005129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。